Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients (pts) with carcinoma of unknown primary site (CUP): Results of a prospective Sarah Cannon Research Institute (SCRI) trial.
Frank A. Greco(Tennessee Oncology), John D. Hainsworth(Sarah Cannon), David R. Spigel(Sarah Cannon), Michael A. Scola(Hematology Oncology Associates), Thabiso W. Chirwa, Samuel Raby(Tennessee Oncology), Mark S. Rubin(Tennessee Oncology), Ralph V. Boccia(Center for Cancer and Blood Disorders), Catherine A. Schnabel(Unknown), Raven Quinn(Tennessee Oncology), Mark G. Erlander(University of California, Los Angeles)
Cited by 4
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
|Annals of Oncology|2020|1.5k
Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2015|1.2k
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
|Breast Cancer Research and Treatment|2017|761
Cloning and Functional Expression of the Human Histamine H<sub>3</sub>Receptor
|Molecular Pharmacology|1999|700